Endothelial progenitor cells in prehypertension
Rossella Di Stefano1, Maria Chiara Barsotti, Francesca Felice
1Cardiovascular Research Laboratory, University of Pisa, Pisa, Italy. r.distefano@ao-pisa.toscana.it
Current Pharmaceutical Design
|August 25, 2011
Summary
Prehypertension increases cardiovascular risk due to endothelial dysfunction. This review explores endothelial progenitor cells
Area of Science:
- Cardiovascular Medicine
- Endothelial Biology
- Regenerative Medicine
Background:
- Prehypertension elevates cardiovascular disease risk and precedes hypertension.
- Endothelial dysfunction, potentially involving endothelial progenitor cells, contributes to this risk.
- Endothelial progenitor cell impairment is linked to atherosclerosis and cardiovascular events.
Purpose of the Study:
- To review current research on the relationship between endothelial progenitor cells and prehypertension.
- To explore potential prevention and treatment strategies for prehypertension.
- To examine the impact of dietary interventions on blood pressure and endothelial progenitor cells.
Main Methods:
- Literature review of recent studies.
- Analysis of data on endothelial progenitor cell number and function in prehypertension.
- Evaluation of dietary intervention effects.
Main Results:
- Prehypertension is associated with endothelial progenitor cell abnormalities.
- These abnormalities may contribute to increased cardiovascular risk.
- Dietary interventions show potential for managing blood pressure and improving endothelial progenitor cell status.
Conclusions:
- Endothelial progenitor cell dysfunction is a key factor in prehypertension-related cardiovascular risk.
- Early intervention, including lifestyle changes like diet, is crucial.
- Further research into endothelial progenitor cells could yield novel therapeutic targets for prehypertension.
Related Concept Videos
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:18Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
01:28Hypertension I: Introduction
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...